Immunostimulatory oligodeoxynucleic molecules

Details Immunostimulatory oligodeoxynucleic molecules Immunostimulatory oligodeoxynucleic molecules

2002-05-17

2010-12-28

Epps-Smith, Janet L. (Department: 1633)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S184100, C424S280100, C435S375000

Reexamination Certificate

active

07858588

ABSTRACT:
Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any X is O or S, any NMP is a 2′ deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2′ deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b integers from 0 to 100 with the proviso that a+b is between 4 and 150, B and E are common groups for 5′ or 3′ ends of nucleic acid molecules, as well as a pharmaceutical composition containing such ODNs.

REFERENCES:
patent: 3725545 (1973-04-01), Maes
patent: 3906092 (1975-09-01), Hilleman et al.
patent: 2002/0132995 (2002-09-01), Agrawal et al.
patent: 2003/0171321 (2003-09-01), Schmidt et al.
patent: 0 468 520 (1992-01-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 98/16247 (1998-04-01), None
patent: WO 98/18810 (1998-05-01), None
patent: WO 98/37919 (1998-09-01), None
patent: WO 98/40100 (1998-09-01), None
patent: WO 98/52581 (1998-11-01), None
patent: WO 98/55609 (1998-12-01), None
patent: WO 99/51259 (1999-10-01), None
patent: WO 99/56755 (1999-11-01), None
patent: WO 01/93905 (2001-06-01), None
patent: WO 01/83503 (2001-11-01), None
patent: WO 02/069369 (2002-09-01), None
patent: WO 03/047602 (2003-06-01), None
Trip et al. Nucleic Acids Research. vol. 5, No. 5, pp. 1539-1549. May 1978.
Andreu and Rivas, “Animal antimicrobial peptides: an overview,”Biopoly, 47:415-433, 1998.
Bailly et al., “PCR-based development of DNA substrates containing modified bases: an efficient system for investigating the role of the exocyclic groups on chemical and structural recognition by minor groove binding drugs and proteins,”Proc. Natl. Acad. Sci., USA, 93:13623-13628, 1996.
Ballas et al., “Induction of NK activity in murine and human cells by CpG motif in oligodeoxynucleotides and bacterial DNA,”J. Immunol., 157:1840-1845, 1996.
Bloom et al., “Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma,”J. of Exp. Med., 185:453-459, 1997.
Buschle et al., “Chemically defined, cell-free cancer vaccines: use of tumor antigen-derived peptides or polyepitope proteins for vaccination,”Gene Ther. Mol. Biol., 1:309-321, 1998.
Buschle et al., “Transloading of tumor antigen-derived peptides into antigen-presenting cells,”Proc. Natl. Acad. Sci., USA, 94:3256-3261, 1997.
Cavanaugh et al., “The activation of murine macrophages and natural killer cells by the partially thiolated double stranded RNA poly(I)-mercapto Poly (C),”Research Communications in Molecular Pathology and Pharmacology, 91:131-147, 1996.
Chace et al., “Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL- 12,”Clin. Immunol. Immunopathol., 84:185-193, 1997.
Davis, “CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen,”J. of Immunology, 160:870-876, 1998.
Deng et al., “Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis,”Nat. Medicine, 5:702-705, 1999.
Ganz and Lehrer, “Antibiotic peptides from higher eukaryotes: biology and applications,”Molecular Medicine Today, 5:292-297, 1999.
Ganz, “Enhanced: defensins and host defense,”Science, 286:420-421, 1999.
Hancock, “Host defence (cationic) peptides. What is their future clinical potential?”Drugs, 57:469-473, 1999.
Hartmann, “CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells,”Proc. Natl. Acad. Sci., USA, 96:9305-9310, 1999.
Hoffmann et al., “Phylogenetic perspectives in innate immunity,”Science, 284:1313-1317, 1999.
Hwang and Greenberg, “Synthesis of 2′-modified oligodeoxynucleotides via on-column conjugation,”J. Org. Chem., 66(2):363-369, 2001.
Kandimalla et al., “Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships,”Bioorganic&Medicinal Chemistry, 9:807-813, 2001.
Klinman et al., “CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ,”Proc. Natl. Acad. Sci., USA, 93:2879-2883, 1996.
Krieg et al., “CpG motifs in bacterial DNA trigger direct B-cell activation,”Nature, 374:546-549, 1995.
Krieg et al., “The role of CpG dinucleotides in DNA vaccines,”Trends in Microbiology, 6:23-27, 1998.
Krieg, “CpG DNA: a novel immunomodulator,”Trends in Microbiology, 7:64, 1999.
Lethe, “Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide,”Eur. J. Immunol., 22:2283-2288, 1992.
Liljeqvist and Stahl, “Production of recombinant subunit vaccines; protein immunogens, live delivery systems and nucleic acid vaccines,”J. of Biotechnology, 73:1-33, 1999.
Lipford et al., “Bacterial DNA as immune cell activator,”Trends Microbiol., 6:496-500, 1998.
Manetti et al., “Polyinosinic acid: polycytidylic acid promotes T helper type 1-specific immune response by stimulating macrophage production of interferon-α and interleukin-12,”Eur J. Immunol., 25:2656-2660, 1995.
Nomura et al., “Site-specific introduction of functional groups into phosphodiester oligodeoxynucleotides and their thermal stability and nuclease-resistance properties,”Nucleic Acids Research, 25(14):2784-2791, 1997.
Oxenius et al., “CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines,”J of Virology, 73:4120-4126, 1999.
Ozaki et al., “Effect of acridine with various linker arms attached to C5 position of 2′-deoxyuridine on the stability of NDA/DNA and DNA/RNA duplexes,”Nucleosides&Nucleotides, 17(5): 911-923, 1998.
Ozaki et al., “Post-synthetic functionalization of oligodeoxyribonucleotides at the 2′-position,”Tetrahedron Letters, 42:677-680, 2001.
Parronchi et al., “Phosphorothioate oligodeoxynucleotides promote the in vitro development of human allergen-specific CD4+ T cells into Thl effectors,”J. Immunol., 163:5946-5953, 1999.
Pisetsky, “Immunostimulatory DNA: a clear and present danger?”Nature Medicine, 3:829831, 1997.
Pisetsky, “The influence of base sequence on the immunostimulatory properties of DNA,”Immunol. Res., 19:35-46, 1999.
Rodrigues et al., “The in vivo cytotoxic activity of CD8+ T cell clones correlates with their levels of expression of adhesion molecules,”J. Exp. Med., 175:895-905, 1992.
Schmidt et al., “Cell-free tumor antigen peptide-based cancer vaccines,”Proc. Natl. Acad. Sci., USA, 94:3262-3267, 1997.
Seela and He, “2′-deoxyuridine and 2′-deoxyisocytidine as constituents of DNA with parallel chain oreintation: the stabilization of the iCd. Gd base pair by the 5-methyl group,”Helvetical Chimica Acta, 83:2527-2540, 2000.
Shinozuka et al., “Multi-functionalization of oligodeoxynucleotide: a facile post-synthetic modification technique for the preparation of oligodeoxynucleotides with two different functional molecules,”Chemi

Affiliated with

Also associated with

Rating

Immunostimulatory oligodeoxynucleic molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunostimulatory oligodeoxynucleic molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunostimulatory oligodeoxynucleic molecules will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4218794